



13 JAN 2006
PCT

PATENT

Attorney Docket No. 38509-0702

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application)	<u>PATENT APPLICATION</u>
)	
Inventor(s): James E. MULLALLY et al.)	
)	Art Unit: Unassigned
Application No.: 10/521,570)	
)	Examiner: Unassigned
Filed: January 18, 2005)	
)	
Title NOVEL INHIBITORS OF UBIQUITIN)	
ISOPEPTIDASES)	

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 and 37 CFR §1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any documents herewith, which are not a statutory bar, is not intended as an admission that such documents constitute prior art against the claims of the present application or are considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

U.S. PATENT AND TRADEMARK OFFICE

RELEVANCE

The foregoing documents came to the Applicants' attention during a search of the corresponding International Application. A copy of the International Search Report setting forth the portion of the references considered relevant by the Examiner is attached.

The Information Disclosure Statement is being filed in compliance with 37 CFR §1.97(b) prior to the mailing date of the first Official Action, therefore, no fee is required in connection with its filing. However, the Commissioner is hereby authorized to charge any deficiency or to credit any overpayment to Deposit Account No. 08-1641.

Applicants respectfully requests that the listed documents be considered by the Examiner and be made of record in this present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Dated: _____

January 13, 2006

By: _____



Paul M. Booth
Registration No. 40,244

HELLER EHRMAN LLP
1717 Rhode Island Avenue, NW
Washington, D.C. 20036-3001
Phone: (202) 912-2000
Fax: (202) 912-2020

Customer No.: **26633**



**LIST OF REFERENCES CITED
BY APPLICANT(S)**

ATTY DOCKET NO.:

38509-0702

SERIAL NO.:

10/521,570

APPLICANT(S):

James E. MULLALLY et al.

FILING DATE:

January 18, 2005

GROUP ART UNIT:

Unassigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE (M/D/Y)	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/A.P./	6,410,512	06/25/02	Mundy et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE (M/D/Y)	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

/A.P./		Database STN, CAPLUS, Division of Molecular Biology (Berlin, Germany), BECHOTSCHIR et al., Accession No. 2001:284801, COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system, Embo Journal, (abstract only), 2001, Vol. 20(7), pages 1630-1639.

EXAMINER

/Anna Pagonakis/

DATE CONSIDERED

12/01/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.